Back to News
May 27, 2026 8:00 AM

Reprogram Biosciences Closes Seed Financing to Advance Tumor Cell Reprogramming Therapeutics

SAN CARLOS, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Reprogram Biosciences, a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, today announced the close of its seed financing. The close brings total capital raised to $6 million since the company's founding in 2025. Investors include Unshackled Ventures, 1517 Fund, and Narya.

Proceeds will support continued development of the company's lead program, expansion of its AI discovery engine, and CMC activities.

Reprogram Biosciences is developing a new class of therapeutics based on in situ cell reprogramming, where mRNA-encoded gene combinations, delivered directly into the tumor, activate the ...